NCT03436654 2026-04-22
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Clinical Trials
974 trialsNCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT05766371 2026-04-17
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT07234981 2026-04-17
PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT07535905 2026-04-17
REVIVE
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06347705 2026-04-16
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03821792 2026-04-15
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07111507 2026-04-15
A Study of Tarlatamab for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT01902680 2026-04-14
CURIEFOCALE
Institut Claudius Regaud
Phase 2 Completed
NCT05960578 2026-04-14
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT02772588 2026-04-13
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04337580 2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT04842890 2026-04-13
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
The New York Proton Center
Phase 2 Active not recruiting
NCT06594926 2026-04-13
WOMBAT
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Recruiting
NCT07220720 2026-04-13
POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions
University of Florida
Phase 2 Recruiting
NCT00859781 2026-04-08
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT05053152 2026-04-08
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Active not recruiting
NCT06632977 2026-04-07
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT07515651 2026-04-07
MIDAS-SBRT
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT07516210 2026-04-07
ART-Hypo
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Not yet recruiting
NCT04709276 2026-04-06
CHAMP
Duke University
Phase 2 Active not recruiting
NCT07512076 2026-04-06
A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer
Sunnybrook Health Sciences Centre
Phase 2 Not yet recruiting
NCT07365423 2026-04-02
TerbinaPro
Swiss Cancer Institute
Phase 2 Recruiting
NCT04300855 2026-04-01
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06734130 2026-04-01
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03496805 2026-03-31
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
Wake Forest University Health Sciences
Phase 2 Completed
NCT03471650 2026-03-30
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT06244004 2026-03-30
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT05826509 2026-03-27
SUGAR
Institut Claudius Regaud
Phase 2 Active not recruiting
NCT04461509 2026-03-25
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT07073794 2026-03-25
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06526299 2026-03-24
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
Phase 2 Recruiting
NCT03787680 2026-03-23
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT04879940 2026-03-23
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03412396 2026-03-19
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07027124 2026-03-19
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT07476677 2026-03-17
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04190446 2026-03-16
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT05751941 2026-03-16
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT01596816 2026-03-13
CKNO-PRO
Centre Oscar Lambret
Phase 2 Completed
NCT03652298 2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2 Terminated
NCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting
NCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07025369 2026-03-13
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Mayo Clinic
Phase 2 Recruiting
NCT07335796 2026-03-13
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07466498 2026-03-12
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
University of Washington
Phase 2 Not yet recruiting
NCT06437574 2026-03-11
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT07142551 2026-03-11
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting